Competitive Landscape Analysis of China's Emerging $3.7B Market
Last Updated: January 28, 2025
China represents the largest gastric cancer market globally with over 260,000 deaths in 2022. With 35% of advanced gastric cancer patients expressing CLDN18.2, and China accounting for 60% of global ADC clinical trials, the country has emerged as the epicenter of CLDN18.2 drug development.2,3
This visualization shows the distribution of different therapeutic modalities targeting CLDN18.2 being developed by Chinese companies. Hover over each segment to see the key players and their development stage.
China's CLDN18.2 pipeline demonstrates exceptional depth with 7 domestically developed drugs in Phase III trials and multiple innovative approaches across all development stages.
| Drug Name | Company | Modality/Technology | Development Stage | Key Indications | Clinical Results | Regulatory Status | Key Differentiators |
|---|---|---|---|---|---|---|---|
| CT041 (satri-cel) | CARsgen | Autologous CLDN18.2 CAR-T | Phase II Complete | 3L+ CLDN18.2+ gastric/GEJ cancer | ORR: 48.6%; DCR: 73.0% 6-mo OS: 81.2%4 | Breakthrough Therapy (China) NDA planned H1 2025 | First-in-class global CLDN18.2 CAR-T; 129 granted patents |
| IBI343 | Innovent Biologics | CLDN18.2 ADC (exatecan) | Phase III | Gastric/GEJ cancer; Pancreatic cancer | Pancreatic: ORR 23.3% PFS: 5.3 months5 | Dual Breakthrough (NMPA/FDA) | Site-specific glyco-conjugation; bystander effect |
| ASKB589 | AskGene Pharma | CLDN18.2 mAb (ADCC-enhanced) | Phase III | 1L CLDN18.2+ gastric cancer | Phase II: ORR 79.2% No DLT up to 20 mg/kg6 | Phase III approved by NMPA | Second-gen humanized mAb; enhanced ADCC |
| LM-302 | LaNova/Turning Point | CLDN18.2 ADC (MMAE) | Phase II/III | 3L+ CLDN18.2+ gastric/GEJ cancer | ORR: 30.6%; DCR: 75.0% mPFS: 7.16 months7 | CDE Breakthrough (Oct 2023) | MMAE payload; strong disease control |
| IBI389 | Innovent Biologics | CLDN18.2×CD3 Bispecific | Phase I/II | CLDN18.2+ pancreatic, gastric cancer | Gastric: ORR 30.8% Pancreatic: ORR 25-30%8 | First-in-class T-cell engager | Manageable CRS; activity in low CLDN18.2 |
| SHR-A1904 | Shanghai Hengrui | CLDN18.2 ADC (Topo-I) | Phase Ib/III | CLDN18.2+ solid tumors | Phase I: ORR ~55% at 6 mg/kg9 | NMPA approved for Phase III | Proprietary Topo-I payload; combo with CAPOX+PD-1 |
This table highlights key programs. Access comprehensive competitive intelligence on all 70+ CLDN18.2 therapeutics in development, including preclinical assets and global partnerships.
Get Full CLDN18.2 Dataset / Book a Call$1.34B for XNW27011 ADC (ex-Greater China)10
Chinese companies retaining Greater China rights while out-licensing globally
Astellas' zolbetuximab approval (Jan 2025) sets the benchmark2
Chinese companies pursuing diverse approaches to differentiate
Navigating China's unique healthcare landscape
With 60% of global ADC trials and the first global CAR-T program, Chinese companies are not followers but leaders in CLDN18.2 development. The depth of the pipeline ensures sustained innovation.3
Unlike single-modality focus elsewhere, Chinese companies are advancing CAR-T, ADCs, bispecifics, and enhanced mAbs simultaneously, providing multiple shots on goal and risk diversification.
With 7 Phase III programs and multiple breakthrough designations, the race for China's $3.7B CLDN18.2 market will be won in the next 24 months. Speed and differentiation are critical.1
This report is for informational purposes only and should not be considered investment advice. The information presented is based on publicly available data and should be independently verified before making any business or investment decisions. This report does not constitute financial advice, investment recommendations, or medical guidance.